JP2018516566A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516566A5
JP2018516566A5 JP2017560327A JP2017560327A JP2018516566A5 JP 2018516566 A5 JP2018516566 A5 JP 2018516566A5 JP 2017560327 A JP2017560327 A JP 2017560327A JP 2017560327 A JP2017560327 A JP 2017560327A JP 2018516566 A5 JP2018516566 A5 JP 2018516566A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
enpp1
pharmaceutical composition
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516566A (ja
JP6995627B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/033236 external-priority patent/WO2016187408A1/en
Publication of JP2018516566A publication Critical patent/JP2018516566A/ja
Publication of JP2018516566A5 publication Critical patent/JP2018516566A5/ja
Priority to JP2021202984A priority Critical patent/JP7390349B2/ja
Application granted granted Critical
Publication of JP6995627B2 publication Critical patent/JP6995627B2/ja
Priority to JP2023196352A priority patent/JP7778392B2/ja
Priority to JP2025191616A priority patent/JP2026015456A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017560327A 2015-05-19 2016-05-19 病的石灰化状態を治療するための組成物およびそれを使用する方法 Active JP6995627B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021202984A JP7390349B2 (ja) 2015-05-19 2021-12-15 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2023196352A JP7778392B2 (ja) 2015-05-19 2023-11-20 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2025191616A JP2026015456A (ja) 2015-05-19 2025-11-12 病的石灰化状態を治療するための組成物およびそれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163500P 2015-05-19 2015-05-19
US62/163,500 2015-05-19
PCT/US2016/033236 WO2016187408A1 (en) 2015-05-19 2016-05-19 Compositions for treating pathological calcification conditions, and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021202984A Division JP7390349B2 (ja) 2015-05-19 2021-12-15 病的石灰化状態を治療するための組成物およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2018516566A JP2018516566A (ja) 2018-06-28
JP2018516566A5 true JP2018516566A5 (enExample) 2019-06-20
JP6995627B2 JP6995627B2 (ja) 2022-02-04

Family

ID=57320640

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017560327A Active JP6995627B2 (ja) 2015-05-19 2016-05-19 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2021202984A Active JP7390349B2 (ja) 2015-05-19 2021-12-15 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2023196352A Active JP7778392B2 (ja) 2015-05-19 2023-11-20 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2025191616A Pending JP2026015456A (ja) 2015-05-19 2025-11-12 病的石灰化状態を治療するための組成物およびそれを使用する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021202984A Active JP7390349B2 (ja) 2015-05-19 2021-12-15 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2023196352A Active JP7778392B2 (ja) 2015-05-19 2023-11-20 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2025191616A Pending JP2026015456A (ja) 2015-05-19 2025-11-12 病的石灰化状態を治療するための組成物およびそれを使用する方法

Country Status (11)

Country Link
US (10) US10583170B2 (enExample)
EP (2) EP4414028A3 (enExample)
JP (4) JP6995627B2 (enExample)
KR (2) KR20250078598A (enExample)
AU (3) AU2016264364B2 (enExample)
CA (2) CA2984947A1 (enExample)
ES (1) ES2983910T3 (enExample)
MX (2) MX391074B (enExample)
PL (1) PL3298140T3 (enExample)
RU (2) RU2757417C2 (enExample)
WO (1) WO2016187408A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5863670B2 (ja) 2010-01-19 2016-02-17 ノースウェスタン ユニバーシティ 核酸および／または他の構成要素を含有している合成ナノ構造体
US9744219B2 (en) 2013-02-13 2017-08-29 Yale University Compositions and methods for treating pathological calcification and ossification
EP3164113B1 (en) 2014-06-04 2019-03-27 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN107109381A (zh) * 2014-12-19 2017-08-29 阿雷克森制药公司 治疗组织钙化的方法
ES2983910T3 (es) 2015-05-19 2024-10-28 Univ Yale Composiciones para tratar afecciones patológicas de calcificación y métodos que usan las mismas
US20180371434A1 (en) 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
BR112019002355A2 (pt) 2016-08-05 2019-07-16 Yale University composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
JP7511469B2 (ja) * 2017-09-27 2024-07-05 イノザイム ファーマ， インコーポレイテッド 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。
CA3099266A1 (en) 2018-05-08 2019-11-14 Yale University Compositions and methods for reducing progression of nephrolithiasis
CA3110498A1 (en) * 2018-08-31 2020-03-05 Yale University Enpp1 polypeptides and methods of using same
KR20210142599A (ko) * 2019-01-18 2021-11-25 이노자임 파마, 인코포레이티드 Enpp1 또는 enpp3 결핍을 수반하는 질환의 치료
EP3914236A4 (en) 2019-01-24 2022-10-26 Northwestern University HIGH-DENSITY LIPOPROTEINMIMETIC NANOPARTICLES USING LIPID-CONJUGATED CORE SCAFFOLDINGS
MX2021012197A (es) * 2019-04-05 2022-01-06 Univ Yale Polipeptidos de ectonucleotido pirofosfatasa (enpp1) y metodos de uso de los mismos.
MX2022014717A (es) * 2020-05-27 2023-02-23 Inozyme Pharma Inc Composiciones y metodos para tratar la enfermedad arterial periferica.
CN116157145A (zh) 2020-06-09 2023-05-23 依诺兹梅制药公司 可溶性enpp1或enpp3蛋白及其用途
AU2021356692A1 (en) * 2020-10-08 2023-05-04 Biomarin Pharmaceutical Inc. Liver specific production of enpp1 or enpp3
IL302954A (en) * 2020-11-19 2023-07-01 Inozyme Pharma Inc Treatment of enpp1 deficiency and abcc6 deficiency
CN118215507A (zh) * 2021-09-24 2024-06-18 依诺兹梅制药公司 冻干enpp1多肽制剂及其用途
WO2025042995A1 (en) * 2023-08-22 2025-02-27 Inozyme Pharma, Inc. Treatment of enpp1 deficiency and abcc6 deficiency in children
WO2025255052A1 (en) * 2024-06-03 2025-12-11 Inozyme Pharma, Inc. Treatment of enpp1 deficiency and abcc6 deficiency in infants

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
CA2179383A1 (en) 1994-01-14 1995-07-20 Ira D. Goldfine Antagonists to insulin receptor tyrosine kinase inhibitor
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
AU2002237667A1 (en) 2000-11-20 2002-05-27 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
US20020183276A1 (en) 2001-03-23 2002-12-05 Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
EP1478772A2 (en) * 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
EP1537140B1 (en) 2001-11-07 2013-01-02 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
EP1928551B1 (en) 2005-06-10 2012-05-30 Althea Technologies, Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
CA2659081C (en) 2006-08-02 2018-01-16 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and use thereof
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
KR100986619B1 (ko) * 2010-03-12 2010-10-08 이상훈 이동통신단말기를 이용한 멀티입출력장치 및 방법
EP2545080B1 (en) 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
KR101772366B1 (ko) 2011-03-11 2017-08-28 알렉시온 파마슈티칼스, 인코포레이티드 Ｎｐｐ１ 융합 단백질
US9744219B2 (en) 2013-02-13 2017-08-29 Yale University Compositions and methods for treating pathological calcification and ossification
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
CN107109381A (zh) 2014-12-19 2017-08-29 阿雷克森制药公司 治疗组织钙化的方法
ES2983910T3 (es) * 2015-05-19 2024-10-28 Univ Yale Composiciones para tratar afecciones patológicas de calcificación y métodos que usan las mismas

Similar Documents

Publication Publication Date Title
ES2906615T3 (es) Tratamiento derivado de citocinas con síndrome de fuga vascular reducido
US10562965B2 (en) Compositions and methods of use for treating metabolic disorders
JP2018502836A5 (enExample)
JP6383122B2 (ja) Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
RU2021129201A (ru) Композиции для лечения патологических состояний кальцификации и способы их применения
JP2024010052A (ja) 組織石灰化の治療方法
JP2010518079A5 (enExample)
EP2968483B1 (en) Subcutaneous administration of adamts13
JP2017518303A5 (enExample)
RU2017123540A (ru) Лечение судорог с использованием щелочной фосфатазы
JP2023027301A (ja) キメラ凝固因子を使用して血友病性関節症を処置する方法
CA2828504A1 (en) Antagonists of the interleukin-1 receptor
JP2018537093A5 (enExample)
US11299528B2 (en) Long acting TRAIL receptor agonists for treatment of autoimmune diseases
ES2883417T3 (es) Composiciones para su uso en el tratamiento o mejora de neuroinflamación, neurodegeneración, dolor neuropático y migraña
WO2015191997A1 (en) Anti-human chemokine (c-c motif) receptor 4 immunotoxins
WO2023154953A1 (en) Gdf15 polypeptides for treating and preventing autoimmune diseases
US20140296154A1 (en) Method of preventing development of psoriatic lesions
US20150366952A1 (en) Methods for reducing fibrosis induced by peritoneal dialysis
KR20240167914A (ko) Enpp1 결핍증 및 abcc6 결핍증의 치료
HK40112655A (zh) 冻干enpp1多肽制剂及其用途
US20250241983A1 (en) Non-opioid methods for treating pain
KR20260058843A (ko) 소아 enpp1 결핍증 및 abcc6 결핍증의 치료
TW202330017A (zh) 凍乾的enpp1多肽調配物及其用途
JPWO2018079701A1 (ja) ラクトフェリン活性を有するタンパク質を含む、抗ガン治療補助剤